Takashi Shoda
Profile
Performance in office
Tenure
Tenure
Background
He joined Sankyo in 1972, served as general manager for Europe and head of the overseas pharmaceutical sales division, then became a Director in June 2001, Managing Director in June 2002, and Representative Director and President of Sankyo in June 2003. Daiichi Sankyo is a holding company that Sankyo and Daiichi Pharmaceutical set up through a share transfer on September 28, 2005, and Takashi Shoda, who came up through Sankyo, became its first President. After the absorption merger in April 2007 he served as Representative Director, President and Chief Executive Officer.
Selection
Sankyo was Japan's second-largest drugmaker and Daiichi Pharmaceutical the sixth, and their simple combined consolidated revenue of ¥919.1 billion exceeded the ¥906.6 billion of Astellas Pharma, due to launch in April 2005. Sankyo's mainstay Mevalotin had lost its Japanese patent, with sales through the third quarter of fiscal 2004 down 17% year on year, and its U.S. patent was expected to expire in April 2006. In summer 2004, Sanofi-Synthelabo, the world's 13th-largest, made a hostile takeover of fourth-ranked Aventis to become the world's second-largest. The new company started with Kiyoshi Morita of Daiichi Pharmaceutical as Chairman and Takashi Shoda of Sankyo as President.
Initiatives
On April 1, 2007, Daiichi Sankyo absorbed Sankyo and Daiichi Pharmaceutical. In November 2008 it made Ranbaxy Laboratories, India's largest generic drugmaker, a subsidiary, acquiring about 64% of its shares for ¥488.3 billion. The U.S. Food and Drug Administration then imposed an import ban on two of Ranbaxy's Indian plants, its share price fell 66% from the purchase price, and in the fiscal year ended March 2009 the company swung to a net loss of ¥215.5 billion on extraordinary losses including a ¥359.5 billion valuation loss. In 2005, the same year as the integration, research on antibody-drug conjugates, later the company's mainstay, had begun with four people.
Career
Career
Sankyo Company, Limited
| Date | Position |
|---|---|
| Apr 1972 | Joined |
| Jan 1999 | General Manager, Europe Department |
| Jun 1999 | General Manager, Overseas Pharmaceuticals Sales Headquarters and Europe Department |
| Jun 2001 | Director |
| Jun 2002 | Managing Director |
| Jun 2003 | Representative Director, President |
Daiichi Sankyo
| Date | Position |
|---|---|
| Sep 2005 | Representative Director, President |
| Apr 2007 | Representative Director, President, Executive Officer |
| Jun 2010 | Stepped down as President |